Disease course and immunophenotype of refractory T-LGL before and after alemtuzumab therapy. (A) Data represent all complete blood counts and white blood cell differentials measured from the initial time of diagnosis. Numbered bars represent the mode and duration of treatment modalities as follows: (1) methotrexate 10 mg/m² twice weekly with prednisone 1 mg/kg (including prednisone taper); (2) cyclosposine 200 mg once a day (days 180-219), 300 mg once a day (days 220-248), and 250 mg once a day (days 249-267); (3) cytoxan 100 mg once a day; (4) ATG 1.5 mg/kg once a day for 4 days; (5) OKT3 20 mg once a day (days 331-339), and 10 mg once a day (days 344-603); (6) pentostatin 4 g/m² every 2 weeks; (7) alemtuzumab 3 mg to 10 mg to 30 mg within first 3 days of therapy, 30 mg 3 times weekly (days 721-760), weekly (days 766-787), every 2 weeks (days 800-currently/1278). Gray dotted line in each graph represents the beginning of alemtuzumab therapy. • denotes a single packed red blood cell transfusion; ▴, platelet transfusion; and (H) denotes hospitalization for neutropenic fever. (B) Flow cytometry was performed on peripheral blood approximately one week prior to the initiation of alemtuzumab therapy (pre-alemtuzumab) and at approximately 80 weeks into alemtuzumab therapy (alemtuzumab). Cells in all dot plots are gated on mononuclear cells based on forward scatter (FSC) and side scatter (SSC) properties. Cells in lower plots are gated on CD45⁺ cells as denoted by arrows. Lower quadrants show isotype-matched control antibody staining.